BTL, the innovator behind the Emsculpt Neo and Emsella wellness technologies, is thrilled to announce its partnership with Alo Wellness Clubs. This collaboration introduces BTL's groundbreaking health solutions to Alo's private wellness clubs in Los Angeles and New York City, giving members exclusive access to next-generation wellness experiences.

Elevating Wellness: Emsculpt Neo and Emsella at Alo Wellness Clubs

Through this partnership, Alo Wellness Clubs will now offer BTL's Emsculpt Neo, a device that combines muscle building and fat reduction using HIFEM+ technology, enhancing functional wellness alongside aesthetics. New protocols promote range of motion and muscle recovery, providing athletes and wellness enthusiasts an elevated health journey. Additionally, BTL's non-invasive Emsella technology will support core health with transformative pelvic floor therapy.

Exclusive Member Experiences and Collaborative Events

This collaboration will feature unique social media activations and wellness events, at Alo's flagship locations, enabling members to experience BTL's advanced technologies firsthand. A special edition of Emsculpt Neo, created in partnership with Alo, will also be launched, further enhancing the premium wellness offerings available to Alo members.

"Partnering with Alo Yoga Wellness Clubs is a win-win for us both," said John Ferris, Vice President of Marketing at BTL. "Together, we're creating an unparalleled wellness experience that aligns with our mission to elevate health and vitality within our communities. We're excited to bring Emsculpt Neo and Emsella to Alo's community, providing transformative wellness solutions to help members thrive."

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO^®, EMFACE^®, EXION™, EMSELLA^®, and others. For more information, visit www.bodybybtl.com

About Alo Yoga

Alo Yoga (Alo) is a Los Angeles-based premium lifestyle brand specializing in luxury activewear with a mission to spread mindful movement, inspire wellness and create community. Since launching in 2007, Alo has become a global leader in activewear design and its franchised fabrics. An acronym for Air, Land, and Ocean, Alo has a studio-to-street mentality that transcends fashion and goes beyond the mat. Alo is available online at www.aloyoga.com and Alo Sanctuaries worldwide.

Media Contact: btl@nouveaucommunications.com

As the prevalence of atrial fibrillation (AF) continues to rise, BTL has announced the successful treatment of the first six patients in the first-in-human feasibility study using a next-generation catheter system designed to streamline AF ablation. This new catheter technology is based on pulsed-field ablation (PFA), a cutting-edge approach that promises to make AF treatment safer, faster, and more effective. The system is undergoing clinical trial under the leadership of renowned experts in cardiology: Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, NY, Dr. Petr Neuzil, Chief of Cardiology at Na Homolce Hospital, Prague and Dr. Štěpán Havránek, Head of Cardiac Electrophysiology at the General University Hospital in Prague.

BTL's upcoming technology features single-shot PVI for efficient pulmonary vein isolation and a versatile design that facilitates intuitive placement in diverse anatomies. This breakthrough enhances procedural reliability and consistency. The forthcoming ablation system is engineered to target all essential areas, extending beyond PVI, with a single device. Enhanced by high-density intracardiac signal acquisition for precise treatment, BTL's next-generation catheter aims to ensure optimal outcomes across different stages of AF. It will offer a comprehensive solution, supporting various ablation sizes from precise linear lesions to area ablations, thereby setting new benchmarks in AF ablation.

Dr. Vivek Reddy of Mount Sinai Hospital, New York, commented, "Our initial clinical results using the BTL catheter are very promising, and I look forward to the continued progress of clinical testing."

Dr. Petr Neužil, Principal Investigator at NNH Hospital in Prague, stated, "I have closely collaborated with BTL in developing this system from its inception, and I am excited to see that the initial results align with the promising outcomes observed in preclinical studies. The first six patients we treated with the Easy Pulz™ catheter at Homolka Hospital, together with my colleague Professor Vivek Reddy, had safe, effective, and straightforward procedures. These early results suggest that this new pulse field technology is very promising, with a lot of potential to make treatments easier and better for our patients."

About BTL
Founded in 1993, BTL is a global leader in medical device innovation, offering advanced solutions across various medical specialties including cardiology, orthopedics, dermatology, and more. With over 300 patents and a team of more than 500 in-house engineers, BTL is dedicated to revolutionizing medical treatments through cutting-edge technology and scientific expertise.
Contact: easypulz.press@btlnet.com

In light of National Emface Days, BTL has released insights from a recent survey conducted by NewBeauty, uncovering key challenges faced by medical weight loss patients when it comes to muscle maintenance and facial aesthetics. The survey, conducted among nearly 2,000 U.S. consumers, highlights widespread awareness of the risks of muscle loss from rapid weight loss but reveals that many patients are not taking proactive steps to preserve muscle tone and youthful appearance.

Survey Highlights:

• Known Risks of Medical Weight Loss: 88.4% of people understand that rapid weight loss can result in muscle loss, yet 33.1% admit they take no action to maintain muscle mass. Additionally, 41.3% place high value on muscle maintenance.
• Challenges with Muscle Building: 68% report difficulty building and toning muscle as they age, regardless of whether they use weight loss medications.
• Concerns Around Aesthetics and Aging: 69.6% say weight loss can make individuals look older, and 72.5% acknowledge that appearance influences their sense of wellness and confidence.

"The findings from this survey show that while people understand the impact of weight loss on their muscle tone and appearance, many are unsure of how to take action to maintain a healthy, youthful look," said John Ferris, VP of Marketing at BTL. "During National Emface Days, we aim to bring awareness to the natural non-invasive options available, such as Emface and Exion, to help patients achieve natural facial rejuvenation without surgery."

The survey findings come at an opportune moment as BTL commemorates the first annual National Emface Days, which celebrates natural beauty and confidence. Emface and Exion are designed to address these concerns through non-invasive treatments. Emface tones facial muscles to restore a natural, youthful foundation, working without injectables, while Exion's advanced radiofrequency technology tightens skin and enhances texture.

"I'm seeing patients in my practice using weight loss drugs on a daily basis, and both Emface and Exion have been highly effective in addressing weight loss management concerns," said Dr. Dendy Engelman, board-certified dermatologist at Shafer Clinic Fifth Avenue. "Emface's proprietary combination of HIFES and RF thermal energies work within to help rebuild and tone facial muscles and connective tissue while Exion's advanced technology not only tightens the skin but also enhances skin's tone and texture. Together, these therapies help improve skin quality and structure by increasing facial muscle tone to create a natural lift."

Survey Methodology:
This survey was conducted via SMS on April 18, 2024, among 1,995 consumers across the United States, focusing on perspectives toward weight loss, muscle maintenance, and non-invasive facial treatments.

For more information about Emface, Exion, and the first annual National Emface Days, visit bodybybtl.com/emfacedays.

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO®, EMFACE®, EXION™, EMSELLA®, and others. For more information, visit www.bodybybtl.com

Media Contact: btl@nouveaucommunications.com 

SOURCE BTL Aesthetics

BTL proudly announces the launch of National Emface Days, a three-day celebration commencing November 12 each year and officially recognized by the National Day Archives on the National Day Registry™. The inaugural event aims to bring together patients and providers to spotlight the Emface experience, which uniquely tones facial muscles to help restore a natural, youthful foundation and complements injectables for an even more striking and refreshed look.

With the recent addition of submentum treatment, Emface now effectively addresses the entire face, including the forehead, cheeks, and submental area, with clinical results showing a remarkable 34% reduction in the submentum on average. National Emface Days will celebrate these advancements and the confidence that Emface inspires in patients seeking non-invasive facial rejuvenation.

"Our goal with Emface is to deliver a holistic, non-invasive facial treatment that enhances natural beauty while helping people feel their best," said John Ferris, VP of Marketing at BTL. "Through National Emface Days, we're celebrating this transformation with our providers and patients, and we look forward to seeing people nationwide come together to confidently share their Emface stories."

Key Highlights of National Emface Days:

• Social Media Sweepstakes: Patients and providers alike can join the celebration by entering the #EmfaceDays sweepstakes, sharing their results and experiences on social media for a chance to win incredible prizes.
• Collaborative Events: BTL has partnered with clinics nationwide to host open houses and "EM-azing Events," where guests can learn about Emface firsthand and enjoy exclusive perks.
• Great Prizes: From Emface treatments to exclusive product bundles, participants in National Emface Days will have opportunities to win exciting rewards.

National Emface Days promises to be an exciting blend of education, celebration, and connection, allowing participants to share their unique experiences and celebrate newfound confidence. For more information, visit bodybybtl.com/emfacedays and join the conversation with #EmfaceDays.

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO^®, EMFACE^®, EXION™, EMSELLA^®, and others. For more information, visit www.bodybybtl.com.

Media Contact: btlaesthetics@nouveaucommunications.com

SOURCE BTL Aesthetics

BTL, a global leader in advanced medical technologies, is thrilled to announce that Emsculpt Neo has received a new FDA clearance for use in stimulating neuromuscular tissue for bulk muscle excitation in the legs or arms for rehabilitative purposes. The Emsculpt's groundbreaking technology revolutionized the body contouring market in 2020 by combining fat reduction and muscle building in one treatment. In 2024, the Emsculpt Neo is set to expand into the wellness market by addressing various medical conditions and further improving patients' quality of life.

Emsculpt Neo is now cleared for:

• Prevention or retardation of disuse atrophy
• Muscle re-education
• Maintaining or increasing range of motion
• Immediate post-surgical prevention of calf muscles to prevent venous thrombosis
• Relaxation of muscle spasms
• Increasing local blood circulation

"Emsculpt Neo not only enhances patients' satisfaction with physical appearance but also improves how they feel and function," said Dr. Mohamed Abdulhamid. "The newfound capabilities of Emsculpt Neo have transformed my patients' lives in ways I never thought possible. After years of struggling with muscle weakness post-surgery, they regained strength and mobility that traditional therapy couldn't provide. Seeing them walk confidently again was truly life-changing."

The market potential for Emsculpt Neo is vast, catering to:

• Post-surgery and rehabilitation patients
• Individuals seeking increased mobility & flexibility
• Active elderly combating age-related deterioration
• Recreational athletes aiming to prevent injuries
• Professional athletes experiencing joint and muscle overload

With over 4 million treatments performed to date, Emsculpt Neo remains the gold standard in body sculpting, delivering unparalleled results for muscle building and fat reduction.

"This FDA clearance opens up new frontiers and possibilities for Emsculpt Neo as a platform that continues to evolve, bringing new patients to practices," said Rohit Mishra, Director of Product Management. "We are committed to innovation that meets the changing needs of our customers, and this advancement reinforces our dedication to excellence in both the aesthetic and medical fields."

David Chmel, CEO of BTL Industries, added, "The rising demand for our treatments and the continued success of the Emsculpt Neo franchise highlights our strong position as we anticipate further growth into Q4 2024 and 2025."

For more information about Emsculpt Neo, please visit emsculptneo.com.

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO®, EMFACE®, EXION™, EMSELLA®, and others. For more information, visit www.bodybybtl.com

CONTACT: btlaesthetics@nouveaucommunications.com

BTL, a global leader in advanced medical technologies, is proud to announce the launch of Clear RF™, the latest innovation for the BTL Exion™ multiplatform system. Exion Clear RF harnesses advanced radio frequency microablation technology to address skin tone, texture, and skin discoloration concerns. This cutting-edge technology is designed to deliver more precise and effective outcomes across various patient profiles and is suitable for use in multiple medical specialties.

Clear RF stands out due to its incorporation of Smart Microablation technology that ensures homogeneous microablation with each pulse, increasing precision and ease of use without unnecessary skin damage. This technology makes Clear RF a game-changer in skin health treatments, allowing providers to maximize consistency and deliver personalized treatments for their patients.

"Clear RF represents a breakthrough in this type of technology, offering standalone value to our clients while seamlessly integrating with the Exion™ multiplatform system," said Daniel Zenker, Director of Product Management at BTL. "By incorporating Clear RF into the Exion system, medical practitioners across specialties can enhance patient outcomes and offer specialized treatments tailored to the unique needs of every patient."

Lesley Clark-Loeser from Precision Skin Institute in Davie FL stated "This really does round out the platform because it allows for us to treat issues of pigmentation, various vascular concerns, texture, tone and overall quality of the skin in quite an amazing way. It is well tolerated by my patients. Clear RF can be done as a standalone procedure, or combined with other applicators on the EXION platform."

Clear RF represents BTL's commitment to advancing medical treatments through innovation and delivering unparalleled results for both providers and patients.

For more information about Clear RF and the Exion multiplatform system, visit www.exion.com.

About BTL Industries

Established in 1993, BTL has become a global leader in the medical device industry, providing innovative solutions across a wide range of medical specialties. With a team of over 3,700 employees in more than 80 countries, BTL supports healthcare professionals in fields such as dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and many others. BTL's portfolio of brands includes EMSCULPT® and EMSCULPT NEO®, EMFACE®, BTL EXION™, EMSELLA® and EMTONE®. For more information, please visit www.bodybybtl.com.